Thursday, November 3, 2011

Has Ranbaxy sold its exclusivity for Lipitor to Teva?????

Teva at its earning call on wednesday announced, it plans to launch an undisclosed drug by YE 2011 and the drug sales would add $0.1 per share to its EPS for full year 2011 (ending december). Looking at the quantum of impact, ( $100m in net income in one month) it could be none other than Lipitor.